Intra-Cellular Therapies Inc. (ITCI) Price to Earnings Multiple
Intra-Cellular Therapies (ITCI) relies on predictable revenues from bipolar disorder and schizophrenia therapies, ensuring stable cash flows. The company's competitive advantages are guaranteed by robust patent protection and recognition within the professional psychiatric community. This price action chart on GURU.Markets shows a PE ratio of -185.50, driven by a sharp surge in profits from the sale of its primary drug and high investor expectations.
Analytical breakdowns for Intra-Cellular Therapies Inc. (ITCI)
- market value and analyst target forecast:
- market capitalization details:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Total Debt to Capital Intra-Cellular Therapies|ITCI - Long-Term Debt to Equity Ratio|Short-Term Indebtedness to Equity Intra-Cellular|ITCI - Company Aggregate Debts|Debt to Book Value Intra-Cellular Therapies, Inc.|ITCI - Company Long-Term Debts|Short-Term Debt Intra-Cellular Therapies|Quick Liquidity intracellulartherapies.com
- earnings and valuation multiples information:
ITCI - Company Net Income|Expected Profit Intra-Cellular Therapies|ITCI - Price to Earnings Ratio|Forward P/E Multiple Intra-Cellular|ITCI - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intra-Cellular Therapies, Inc.|ITCI - Operating profit EBITDA|Net earnings per share (EPS TTM) Intra-Cellular Therapies|ITCI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months intracellulartherapies.com|ITCI - Net earnings per share growth this year|Expected earnings per share trend next year Intra-Cellular Therapies
Summary company analysis:ITCI intracellulartherapies.com
This metric is calculated as the ratio of market capitalization to net income, reflecting the sensitivity of business value to operational efficiency. This ratio measures the investment payback period based on current profitability. For Intra-Cellular Therapies (ITCI), it depends critically on Caplyta commercial sales and regulatory price caps. Any margin compression resulting from patent risks will be immediately reflected in the valuation. By analyzing the current P/E multiple, an investor can distinguish fundamental undervaluation from a systemic decline in revenue.
Key competitors
biogen.com (BIIB) - Business Payback Period|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|Regencell Bioscience Ltd - Price to Earnings Multiple|Axsome Therapeutics Inc - Price to Earnings Ratio|Market Price to Net Income Ratio ACAD (ACADIA Corp)|XENE - Price to Earnings Ratio|Company Value to Net Income VKTX (vikingtherapeutics.com)|SUPN: P/E Multiple|Catalyst Pharma (CPRX) - P/E Multiple|Price to Earnings Ratio DNLI|HRMY - Market Cap to Net Income Ratio|P/E Multiple BHVN|Price to Earnings Ratio amylyx.com AMLX|P/E Multiple TRVI (Trevi Therapeutics, Inc.)|Praxis Precision Medicines Inc (PRAX) - Market Cap to Earnings|AVXL - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|prothena.com (PRTA) - Price to Earnings Ratio|ALEC (Alector) - Price to Earnings Ratio|Price to Earnings Ratio ANNX|P/E Multiple Omeros Corp.|Price to Earnings Ratio Neurogene Corp (NGNE)|Price to Earnings Ratio ACIU (AC Immune Inc)|P/E Multiple VYGR (Voyager Therapeutics)|P/E Multiple neumoratx.com NMRA|SCLX - Price to Earnings Ratio|Company Value to Net Income TVGN (Tevogen Bio Holdings Inc.)|ACOG (alphacognition.com) - Price to Earnings Ratio|Cognition Therapeutics Inc. - Company Value to Net Income|Price to Earnings Ratio IKT|SAVA (cassavasciences.com) - Market Price to Net Income Ratio|P/E Multiple ASRT|COYA (coyatherapeutics.com) - Company Value to Net Income|P/E Multiple VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Market Cap to Earnings|ABOS - Price to Earnings Ratio|Company Value to Net Income CRVO (cervomed.com)|ATHE: P/E Multiple|Clene (CLNN) - P/E Multiple|Price to Earnings Ratio PepGen Inc|Jupiter Neurosciences, Inc. - Market Cap to Net Income|P/E Multiple RLMD|Business Payback Period annovisbio.com|P/E Multiple GRCE (Grace Therapeutics)|Firefly Neuroscience, Inc. (AIFF) - Market Cap to Earnings|KLTO - Price to Earnings Ratio|Business Payback Period NeuroSense Therapeutics NRSN|RVPH: P/E Multiple|MTVA - Business Payback Period|Price to Earnings Ratio NRXS|HSDT (Helius Medical Technologies Inc.) - Market Price to Net Income Ratio|P/E Multiple PASG|Price to Earnings Ratio bionomics.com.au NEUP|P/E Multiple NERV (Minerva Neurosciences)|Business Payback Period athira.com (ATHA)|ADXN - Price to Earnings Ratio|ALZN (Alzamend Neuro, Inc.) - Price to Earnings Multiple|CYCN: P/E Multiple|Market Cap to Earnings Protagenic Therapeutics, Inc. (PTIX)|Price to Earnings Ratio KTTA|P/E Multiple Cortigent Medical|Price to Earnings Ratio Avenue Therapeutics, Inc. (ATXI)|BCLI (Brainstorm Cell Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Cara Therapeutics, Inc CARA|Chromocell (CHRO) - Market Cap to Earnings|Eliem - P/E Multiple|Business Payback Period longboardpharma.com LBPH|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|Price to Earnings Multiple NKGN|Price to Earnings Ratio NRBO|SAGE (Sage Therapeutics Inc) - Market Price to Net Income Ratio|Price to Earnings Ratio Synaptogenix, Inc. (SNPX)|TRVN (trevena.com) - Company Value to Net Income|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|P/E Multiple anewmeds.com WENA|CERE: Price to Earnings Ratio
